Clinical Science Review: Update on Trimetrexate, a Folate Antagonist with Antineoplastic and Antiprotozoal Properties
- 1 January 1991
- journal article
- review article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 9 (2) , 159-172
- https://doi.org/10.3109/07357909109044227
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Trimetrexate in advanced carcinoma of the esophagusInvestigational New Drugs, 1988
- Trimetrexate for the Treatment ofPneumocystis cariniiPneumonia in Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1987
- Potent Effect of Trimetrexate, a Lipid-Soluble Antifolate, on Toxoplasma gondiiThe Journal of Infectious Diseases, 1987
- Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate.Journal of Clinical Investigation, 1987
- Methotrexate resistant cells at targets for selective chemotherapyAdvances in Enzyme Regulation, 1985
- Trimetrexate: a new antifol entering clinical trialsInvestigational New Drugs, 1985
- Biochemical pharmacology of the lipophilic antifolate, trimetrexateAdvances in Enzyme Regulation, 1984
- Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitroBiochemical Pharmacology, 1984
- 2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (TMQ), a potent non-classical folate antagonist inhibitor—IBiochemical Pharmacology, 1979
- Multivariate analysis and quantitative structure-activity relationships. Inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolinesJournal of Medicinal Chemistry, 1979